BRAF and neoplasm: Evidence of acquired resistance to BRAF and MEK inhibitors induced by tumour‐associated CD20+ B‐cells came from an in vitro analysis, which suggested this was mediated by B‐cell production of growth factor IGF‐1 (Somasundaram et al., 2017).